Please assess the completion status of the following clinical trial:

Trial Title: Open-label Study of the Safety and Activity of Oprozomib in Patients With Hematologic Malignancies

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
INCLUSION CRITERIA:~Phase 1b~* Histologically confirmed diagnosis of a hematologic malignancy, excluding patients with acute leukemia or MDS.~* Relapsed after standard therapy for their malignancy and considered to be an appropriate candidate for a Phase 1 clinical study by their treating physician.~Phase 2~* Multiple myeloma with measurable disease~* Waldenström macroglobulinemia with symptomatic relapse~* Eastern Cooperative Oncology Group (ECOG) Performance Status 0-2.~Ethical/Other~* Patients must sign a written informed consent form in accordance with federal, local, and institutional guidelines.~* Female patients of childbearing potential must have a negative serum or urine pregnancy test and agree to use effective contraception. Male patients must use an effective barrier method of contraception.~EXCLUSION CRITERIA:~* Chemotherapy with approved or investigational anticancer therapeutics, including steroid therapy intended to treat underlying malignancy, within 3 weeks prior to first dose or 6 weeks for antibody therapy.~* Radiation therapy within 3 weeks prior to first dose. Radioimmunotherapy within 8 weeks prior to first dose. Localized radiation therapy within 1 week prior to first dose.~* Immunotherapy within 3 weeks prior to first dose (except for antibody therapy, where 6 weeks is required).~* Prior stem cell transplant (SCT) therapy (autologous SCT within the prior 8 weeks; allogeneic SCT within the prior 16 weeks). Patients with prior allogeneic SCT should not have evidence of moderate-to-severe graft-vs-host disease (GvHD; as defined in Filipovich 2005).~* Evidence of central nervous system (CNS) lymphoma.~* Prior treatment with carfilzomib unless in the phase 2.~* Major surgery within 3 weeks prior to first dose.~* Symptomatic Congestive heart failure, ischemia, conduction abnormalities, or myocardial infarction within 6 months.~* Acute active infection requiring systemic antibiotics, antivirals, or antifungals.~* Known or suspected human immunodeficiency virus (HIV) infection or patients who are HIV seropositive.~* Active hepatitis A, B, or C infection.~* Significant neuropathy (Grade 3, Grade 4, or Grade 2 with pain) at the time of the first dose.~* Patients with pleural effusions requiring routine thoracentesis or ascites requiring routine paracentesis.~* History of previous clinically significant GI bleed in the last 6 months prior to first dose.~* Female patients who are pregnant or lactating.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- QDx2 Dosing Schedule (Type: EXPERIMENTAL): QDx2 is defined as patients receiving Oprozomib Tablets once daily on Days 1, 2, 8, and 9 of the 14-day cycle.~The schedule will be evaluated in Phase 1 for MTD in patients with hematologic malignancies, and will also be evaluated in Phase 2 for ORR in patients with MM and WM.
- QDx5 Dosing Schedule (Type: EXPERIMENTAL): QDx5 is defined as patients receiving Oprozomib Tablets once daily on Days 1 to 5 of the 14-day cycle.~The schedule will be evaluated in Phase 1 for MTD in patients with hematologic malignancies, and will also be evaluated in Phase 2 for ORR in patients with MM and WM.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues